204 related articles for article (PubMed ID: 36519323)
1. CCRL2 affects the sensitivity of myelodysplastic syndrome and secondary acute myeloid leukemia cells to azacitidine.
Karantanos T; Teodorescu P; Arvanitis M; Perkins B; Jain T; DeZern AE; Dalton WB; Christodoulou I; Paun BC; Varadhan R; Esteb C; Rajkhowa T; Bonifant C; Gondek LP; Levis MJ; Yegnasubramanian S; Ghiaur G; Jones RJ
Haematologica; 2023 Jul; 108(7):1886-1899. PubMed ID: 36519323
[TBL] [Abstract][Full Text] [Related]
2. The role of the atypical chemokine receptor CCRL2 in myelodysplastic syndrome and secondary acute myeloid leukemia.
Karantanos T; Teodorescu P; Perkins B; Christodoulou I; Esteb C; Varadhan R; Helmenstine E; Rajkhowa T; Paun BC; Bonifant C; Dalton WB; Gondek LP; Moliterno AR; Levis MJ; Ghiaur G; Jones RJ
Sci Adv; 2022 Feb; 8(7):eabl8952. PubMed ID: 35179961
[TBL] [Abstract][Full Text] [Related]
3. Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.
Cabezón M; Malinverni R; Bargay J; Xicoy B; Marcé S; Garrido A; Tormo M; Arenillas L; Coll R; Borras J; Jiménez MJ; Hoyos M; Valcárcel D; Escoda L; Vall-Llovera F; Garcia A; Font LL; Rámila E; Buschbeck M; Zamora L;
Clin Epigenetics; 2021 Jan; 13(1):9. PubMed ID: 33446256
[TBL] [Abstract][Full Text] [Related]
4. Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine.
Shabanova I; Cada M; Johnston DL; Abbott LS; Leung EW; Schechter T; Dror Y; Klaassen RJ
J Pediatr Hematol Oncol; 2020 Apr; 42(3):170-174. PubMed ID: 32134844
[TBL] [Abstract][Full Text] [Related]
5. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
[TBL] [Abstract][Full Text] [Related]
6. Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.
Müller-Thomas C; Rudelius M; Rondak IC; Haferlach T; Schanz J; Huberle C; Schmidt B; Blaser R; Kremer M; Peschel C; Germing U; Platzbecker U; Götze K
Haematologica; 2014 Oct; 99(10):e179-81. PubMed ID: 24972774
[No Abstract] [Full Text] [Related]
7. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine.
Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR
Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320
[TBL] [Abstract][Full Text] [Related]
8. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
9. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
10. Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Cluzeau T; Furstoss N; Savy C; El Manaa W; Zerhouni M; Blot L; Calleja A; Dufies M; Dubois A; Ginet C; Mounier N; Garnier G; Raynaud S; Rohrlich PS; Peterlin P; Stamatoullas A; Chermat F; Fenaux P; Jacquel A; Robert G; Auberger P
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31881723
[TBL] [Abstract][Full Text] [Related]
11. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cogle CR; Scott BL; Boyd T; Garcia-Manero G
Oncologist; 2015 Dec; 20(12):1404-12. PubMed ID: 26463870
[TBL] [Abstract][Full Text] [Related]
12. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
13. Gene Expression and DNA Methylation Profiling Suggest Potential Biomarkers for Azacitidine Resistance in Myelodysplastic Syndrome.
Kim DY; Shin DY; Oh S; Kim I; Kim EJ
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731939
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.
Falantes JF; Trujillo P; Piruat JI; Calderón C; Márquez-Malaver FJ; Martín-Antonio B; Millán A; Gómez M; González J; Martino ML; Montero I; Parody R; Espigado I; Urbano-Ispizua A; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):236-44. PubMed ID: 25487600
[TBL] [Abstract][Full Text] [Related]
16. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.
Mpakou V; Spathis A; Bouchla A; Tsakiraki Z; Kontsioti F; Papageorgiou S; Bazani E; Gkontopoulos K; Thomopoulos T; Glezou I; Galanopoulos A; Symeonidis A; Diamantopoulos PT; Viniou NA; Kontandreopoulou CN; Zafeiropoulou K; Kotsianidis I; Lamprianidou E; Foukas P; Mpamias A; Pappa V
Hematol Oncol; 2021 Apr; 39(2):231-242. PubMed ID: 33332639
[TBL] [Abstract][Full Text] [Related]
17. The nonsteroidal anti-inflammatory drug Exisulind selectively induces apoptosis via JNK in secondary acute myeloid leukemia after myelodysplastic syndrome.
Czibere A; Prall WC; Zerbini LF; Grall F; Craigie EC; Ulrich SD; Giagounidis AA; Haas R; Libermann TA; Aivado M
Cell Cycle; 2005 Jun; 4(6):812-7. PubMed ID: 15970671
[TBL] [Abstract][Full Text] [Related]
18. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
Bewersdorf JP; Zeidan AM
Leuk Lymphoma; 2020 Oct; 61(10):2295-2312. PubMed ID: 32421403
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of epigenetic agents for older patients with acute myeloid leukemia and myelodysplastic syndrome in randomized controlled trials: a systematic review and network meta-analysis.
Oh S; Kim E
Clin Exp Med; 2023 Oct; 23(6):2705-2714. PubMed ID: 36964818
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of SPINT2/HAI-2 by Azacytidine in bone marrow mesenchymal stromal cells affects leukemic stem cell survival and adhesion.
Roversi FM; Cury NM; Lopes MR; Ferro KP; Machado-Neto JA; Alvarez MC; Dos Santos GP; Giardini Rosa R; Longhini AL; Duarte ADSS; Pericole FV; Favaro P; Yunes JA; Saad STO
J Cell Mol Med; 2019 Feb; 23(2):1562-1571. PubMed ID: 30484958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
